Rivas Medical Weight Loss

Rivas Medical Weight Loss operates a physician-supervised weight management practice in Forest Hill, Maryland, with telehealth services extending to Virginia and Florida. The clinic structures its programs around GLP-1 receptor agonist therapy, specifically semaglutide and tirzepatide, integrated with metabolic assessment protocols that include body composition analysis and insulin sensitivity testing. Each patient receives individualized dosing schedules based on baseline metabolic markers and response tracking, with medication titration adjusted according to documented weight loss velocity and glycemic control parameters.

The clinic's treatment protocols center on two primary peptide medications: semaglutide, a GLP-1 agonist that reduces appetite through hypothalamic signaling and delays gastric emptying, and tirzepatide, a dual GIP/GLP-1 receptor agonist that activates both incretin pathways for enhanced metabolic effects. Patients undergo initial metabolic panels including fasting glucose, hemoglobin A1c, lipid profiles, and thyroid function tests to establish baseline parameters and identify contraindications. The practice treats obesity with BMI over 30, overweight patients with BMI over 27 presenting comorbid conditions such as type 2 diabetes or hypertension, insulin resistance documented through HOMA-IR scoring, and metabolic syndrome meeting ATP III diagnostic criteria. Treatment plans incorporate weekly or biweekly peptide injections with dose escalation protocols designed to minimize gastrointestinal side effects while achieving target weight reduction of 1-2 pounds per week.

The Forest Hill clinic provides both in-person consultations at its Maryland location and telehealth appointments for patients in Maryland, Virginia, and Florida, allowing for flexible monitoring without geographic constraints. Initial visits include comprehensive metabolic evaluation, body composition scanning using bioelectrical impedance analysis to measure fat mass versus lean tissue, and review of prior weight loss attempts to identify previous barriers to success. Follow-up appointments occur every 2-4 weeks during the active weight loss phase, with providers reviewing patient-reported food logs, tracking weight trends against predicted loss curves, and adjusting peptide dosages based on tolerance and efficacy markers. The practice maintains structured communication protocols for patients experiencing side effects, with clinical staff available to address nausea, constipation, or injection site reactions through dosing modifications or adjunctive therapies.

Patients beginning treatment at Rivas Medical Weight Loss complete an intake process that documents current medications, previous bariatric interventions, eating behavior patterns, and weight history to customize the therapeutic approach. The clinic's protocols require regular monitoring of kidney function and pancreatic enzymes in patients receiving GLP-1 therapy, with laboratory testing scheduled at baseline, 3 months, and 6 months to detect potential adverse effects. Providers educate patients on proper subcutaneous injection technique for self-administration, optimal injection sites to rotate for absorption consistency, and refrigeration requirements for peptide storage. The practice emphasizes that peptide therapy functions as one component within a broader metabolic intervention, requiring concurrent attention to macronutrient distribution, meal timing, and physical activity patterns to sustain weight loss beyond the medication period.

The clinic's telehealth platform enables patients across Maryland, Virginia, and Florida to access physician-supervised GLP-1 therapy without requiring travel to the Forest Hill office, with medications shipped directly to patient addresses and virtual check-ins conducted via secure video conferencing. This delivery model allows the practice to serve patients in suburban and rural areas where specialized weight management services may be limited, while maintaining the clinical oversight necessary for safe peptide administration. Rivas Medical Weight Loss structures its programs with defined duration phases, typically spanning 6-12 months of active treatment followed by maintenance protocols, with success metrics tracked through body composition changes rather than scale weight alone to account for lean mass preservation during caloric restriction.